Riskpilot← Back to searchSign inGet full accessPharma Systems Aktiebolag
ABActiveOrg 5563620854Datavägen 5Manufacture of medical and dental instruments and supplies · NACE 3250Est. 19891-4 employees
Revenue 2025
SEK 24,8M
+17% vs 2024
EBITDA margin
-8.5%
+41% vs 2024
Equity ratio
16.1%
Financial strength
Net profit 2025
SEK 317K
+330% vs 2024
| Revenue | SEK 24,8M | +17% |
| EBITDA | SEK -2,1M | +41% |
| Net profit | SEK 317K | +330% |
| Total assets | SEK 16,8M | -7% |
| Equity | SEK 2,7M | +13% |
| Employees | — | — |
Legal name
Pharma Systems Aktiebolag
Org number
5563620854
Legal form
Aktiebolag
NACE code
3250 · Manufacture of medical and dental instruments and supplies
Founded
13 juni 1989
Share capital
SEK 206 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva tillverkning, försäljning och vidareförädling av plastprodukter huvudsakligen för sjukvård samt driva därmed förenlig verksamhet.
Address
Datavägen 5
Email
ekonomi@pharmasys.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 37 000 | 28 277 | 36 343 | 21 260 | 24 800 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 6 733 | 4 294 | 411 | −3 554 | −2 112 |
| Depreciation & amort. | −670 | −303 | −225 | −450 | −31 |
| EBIT | 6 063 | 3 991 | 186 | −4 004 | −2 143 |
| Net financials | 68 | 39 | −185 | −233 | −152 |
| Profit before tax | 5 589 | 5 170 | 975 | −135 | 444 |
| Tax | −1 208 | −1 111 | −259 | −3 | −127 |
| Net profit | 4 381 | 4 059 | 716 | −138 | 317 |
| Item | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 40 897 | 32 616 | 17 151 | 18 138 | 16 783 |
| Equity | 29 126 | 19 185 | 2 525 | 2 386 | 2 704 |
| Long-term debt | 0 | 2 604 | 3 537 | 2 021 | 505 |
| Short-term debt | 3 978 | 4 173 | 5 410 | 8 454 | 9 286 |
| Total debt | 3 978 | 6 777 | 8 947 | 10 475 | 9 791 |
EBITDA margin
-8.5%
This company
15.8%
Market median
-154% vs market
20202025
Equity ratio
16.1%
This company
38.2%
Market median
-58% vs market
20202025
Return on equity
11.7%
This company
18.4%
Market median
+36% vs market
20202025
Net profit margin
1.3%
This company
8.1%
Market median
-84% vs market
20202025
Asset turnover
1.48×
This company
1.12×
Market median
+32% vs market
20202025
Debt / equity
5.21×
This company
0.62×
Market median
-740% vs market
20202025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-01-01 – 2023-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AT Chief Executive Officer | Chief Executive Officer | 2020 |
SD Chief Auditor | Chief Auditor | 2020 |
| Former (2) | ||
AE Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
AG Chief Auditor | Chief Auditor | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Former (4) | ||
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Chairman | 2020 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pharma Systems Aktiebolag (this company)
PHARMA SYSTEMS EESTI OÜPharma Systems Eesti OüBoard members of Pharma Systems Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anette Elisabet Hedman Danielsson | Chief Executive Officer | 0 companies |
| Alf Gunnar Rune Sjödelius | Chief Auditor | 0 companies |
| Anna Therese Grundén | Chief Executive Officer | 0 companies |
| Sven Daniel Larsson | Chief Auditor | 0 companies |
| Anja Margareta Thoresson | Board of Directors | 0 companies |
| Göran Arthur Lindén | Chairman | 0 companies |
| Claes Robert Fleming Stjernfelt | Board of Directors | 0 companies |
| Kent Roody Jogan Hedman | Board of Directors | 0 companies |
| Hans Lennart Svanborg | Board of Directors | 0 companies |
| Mia Marina Berg | Board of Directors | 0 companies |
| Claes Olov Lundberg | Board of Directors | 0 companies |
| Jan Hedman | Board of Directors | 0 companies |
| Åsa Katarina Nordlander | Chairman | 0 companies |
| Stefan Manne Hägelmark | Board of Directors | 0 companies |